ArticleTranslational andrology and urology2026
METS-VF outperforms traditional adiposity indices in predicting overactive bladder risk: a NHANES-based cross-sectional study.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Overactive bladder (OAB) represents a frequent urological disorder with a multifaceted etiology, yet the implication of visceral adiposity in its pathogenesis remains underexplored. Our objective was to evaluate the connection between the metabolic score for visceral fat (METS-VF) and OAB risk in a nationally representative USA population, besides comparing METS-VF predictive utility against conventional adiposity indices. Methods: This cross-sectional analysis utilized National Health and Nutrition Examination Survey (NHANES) data from 6,366 participants. Multivariable logistic regression (LR) analysis, subgroup analyses, and receiver operating characteristic (ROC) were employed to ascertain the interaction of METS-VF with OAB. Furthermore, ROC analysis was implemented to contrast METS-VF diagnostic capabilities against body mass index (BMI), waist circumference (WC), and waist-to-height ratio (WHtR). Results: The analysis included 6,366 participants; of them, 4,536 were diagnosed with OAB, showing a significant link between METS-VF and OAB (P<0.001). Notably, OAB prevalence increased progressively across METS-VF quartiles (Q1: 52.20%, Q2: 64.76%, Q3: 74.56%, Q4: 85.19%). After full adjustment for covariates, METS-VF remained significantly related to OAB, revealing a positive association [odds ratio (OR) =1.38, 95% confidence interval (CI): 1.22-1.57]. Subgroup analyses consistently elucidated a significant interconnection between METS-VF and OAB across various demographics. The restricted cubic spline (RCS) analysis results demonstrated a significant non-linear association between METS-VF and OAB (P=0.004). Moreover, METS-VF displayed a superior predictive ability for OAB, unlike conventional indices, including BMI, WC, and WHtR. Conclusions: The METS-VF, an innovative composite indicator of visceral adiposity and metabolic dysfunction, serves as a robust and reliable predictor of OAB risk among adults in the USA. Its enhanced predictive capacity relative to traditional adiposity metrics highlights its potential application in clinical risk assessment and public health strategies aimed at mitigating visceral obesity-related urological conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.